Catalent Invests $14 Million at Softgel Facility in Germany

April 24, 2019

Expansion at the Eberbach, Germany facility includes two Vegicap encapsulation lines, printing, inspection, and packaging capabilities.

Catalent has announced a $14 million expansion to expand integrated turnkey softgel capabilities at its facility in Eberbach, Germany, including two new encapsulation lines for Catalent’s proprietary Vegicaps technology.

The new Vegicap lines will be completed by September 2019, Catalent reported in an April 23, 2019 press statement.  Other aspects of the investment-including new printing technology, a vision inspection system, expansion of the facility’s softgel coating capabilities, and the additional packaging capacity-are scheduled for completion by mid-2020?

The site will also increase the workforce by more than 10% across operations, quality control, and related supporting functions.

“The Eberbach facility is our biggest softgel development and manufacturing facility in Europe with a capacity of more than 10 billion softgel capsules per year,” commented Raoul Bernhardt, general manager of the Eberbach facility in the press statement. “This investment reflects the importance of the site and will enable us to better serve our customers with increased volumes and turnkey services.”

The 360,000-sq.-ft. facility offers integrated softgel manufacturing services for prescription pharmaceuticals, over-the-counter pharmaceuticals, nutritional supplements, medical devices, and animal health products, as well as highly potent and cytotoxic compounds within an isolated, self-contained cytotoxic suite.

Source: Catalent Pharma Solutions